Establishment of a Neutrophil elastase Activity home test for the Better management and treatment of Lung Exacerbations

Informations projet

ENABLE

N° de convention de subvention: 651158

DOI 10.3030/651158

Projet clôturé

Date de signature de la CE 26 Septembre 2014

Date de début 1 Octobre 2014

Date de fin 31 Mars 2015

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 71 429,00

Contribution de l’UE € 50 000,00

Coordonné par

PROAXSIS LTD
Royaume-Uni

Objectif

Chronic obstructive airways disease (COPD) is a leading cause of death of increasing prevalence worldwide and is characterised by progressive airflow reduction, breathing difficulties and irreversible lung damage. Management of COPD varies extensively, with patients not receiving proactive disease management at greater risk of poorer outcomes. Routine measurement of an active protease (enzyme) biomarker called neutrophil elastase (NE) will empower clinicians and patients to adopt proactive approaches to disease management and treatment, reducing exacerbations and emergency hospital admissions.

Our goal is therefore to develop a novel, simple to use ‘Point-of-Care’ (PoC) test that will improve patient outcome and reduce the clinical, societal and economic burdens associated with chronic respiratory disease (CRD). The activity of NE (NEa) in the airways is known to correlate with the severity of several CRDs such as COPD, cystic fibrosis (CF) and bronchiectasis, and importantly is highly predictive of infection and an early marker of exacerbation. Our novel device, NEATstikTM (Neutrophil Elastase Airways Test), will enable the rapid measurement of NEa at PoC and has been designed for home use (patient self-management) in mind, with a view to remote monitoring. It is expected that this test will help to improve patient management and outcome, with the ultimate goal of reducing the individual, European and global burden of COPD.

This phase 1 proposal is to provide a feasibility assessment which will maximise the potential for success the clinical validation of NEATstikTM, a PoC device that will enable the proactive management of chronic respiratory diseases such as COPD.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• sciences médicales et de la santé › sciences de la santé › maladie infectieuse › virus à ARN › coronavirus
• sciences médicales et de la santé › médecine fondamentale › pharmacologie et pharmacie › produit pharmaceutique › antibiotique
• sciences médicales et de la santé › médecine clinique › oncologie
• sciences sociales › économie et affaires › économie › économie sanitaire
• sciences naturelles › sciences biologiques › biochimie › biomolécule › protéines › enzyme

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thème(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Appel à propositions

H2020-SMEInst-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-1-2014

Régime de financement

SME-1 -

Coordinateur

PROAXSIS LTD

• Contribution nette de l'UE: € 50 000,00
• Adresse: 63 University Road ; BT7 1NF Belfast ; Royaume-Uni
• PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui:
  Région
  Northern Ireland › Northern Ireland › Belfast
• Région: Northern Ireland › Northern Ireland › Belfast
• Type d’activité: Organismes privés à but lucratif (à l’exclusion des établissements d’enseignement supérieur ou secondaire)
• Coût total: € 71 429,00